🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareThe GLP Lounge Community Rules — Updated January 2026

The GLP Lounge Community Rules — Updated January 2026

Admin Mon, Feb 12, 2024 at 6:40 PM 534 replies 45,480 viewsPage 1 of 20
This thread has been pinned by mike_mod.
This thread has been locked by Admin. No further replies are accepted.
This thread is more than 28 months old. Information may be outdated. Consider searching for more recent discussions.
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 12, 2024 at 6:40 PM#1

The GLP Lounge Community Rules — Updated January 2026

Public Square is a small room with a long memory. These are the house rules; they are short because we would rather enforce a few things properly than list twenty and mean none of them.

The rules

  1. Argue with the claim, never the person. Hard disagreement is the point of this board. Contempt is not, and it is the one thing that gets a post removed without discussion.
  2. Say where it came from. A clinical claim needs a source, and “I read it somewhere” is an invitation to go and find where. Nobody is asked to cite their own experience — only to label it as experience.
  3. No purchase links, anywhere. Not in a post, not in a signature, not by private message. Vendor discussion belongs in the review sections; vendor traffic belongs somewhere else.
  4. Nothing here is medical advice, including anything written by a member who tells you what they do for a living. Take it to somebody who can examine you.
  5. Declare an interest. If you have any commercial relationship with a supplier, say so in the post. Undisclosed promotion is the only offence here with no second chance.
  6. Search first. Most questions have been answered at length, usually better than they will be answered again today.
  7. Correct yourself in public. Editing a mistake away helps nobody; a correction underneath it helps the next person who made the same one.
  8. No politics, no religion, and no diagnosing strangers.

How this is enforced

First time, a note from a moderator. Second time, a week off. Third time, permanently, and we do not debate it in the thread. Undisclosed promotion and scam posts skip straight to the third step.

Disagree with a decision? Message the moderators. Arguing about moderation inside a thread derails the thread, which is the actual harm.

— Admin · reviewed quarterly
9 4PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 6 others
Reply Quote Save Share Report
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Feb 12, 2024 at 7:43 PM#2
Admin said:
The GLP Lounge Community Rules — Updated January 2026 Public Square is a small room with a long memory.

Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.

8 3lucas_SP_BR, lisa_labSD, adam_van and 5 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Feb 12, 2024 at 8:46 PM#3
Admin said:
The GLP Lounge Community Rules — Updated January 2026 Public Square is a small room with a long memory.

This is where I part company with the consensus forming above. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

7 2COA_Karl, MikeFit_NJ, InsuranceTom and 4 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
Feb 12, 2024 at 9:49 PM#4

This one has a reasonably settled answer, so here it is. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Feb 13, 2024 at 12:49 AM
6 1InsuranceTom, WendyG_ATL, SaraMom3 and 3 others
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Feb 13, 2024 at 3:50 AM#5
InsuranceTom said:
Agreed, and subgroup analyses deserve particular suspicion.

Can confirm the pattern InsuranceTom describes. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.

5 0mike_mealprep, NicoleRaleigh, james_edin and 2 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register